TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BerGenBio ASA ( (BRRGF) ) just unveiled an announcement.
Oncoinvent ASA has announced a fully underwritten rights issue, raising NOK 130 million through the issuance of 260,000,000 new shares. Additionally, the company is issuing 31,199,997 new shares as an underwriting commission, reflecting strategic financial maneuvers to support its ongoing operations and clinical trials, which could strengthen its market position in the biotechnology sector.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer treatment. Their lead product, Radspherin®, utilizes radium-224 to target micro-metastases post-surgery, with ongoing clinical trials in the US, UK, and Europe showing promising early efficacy data.
YTD Price Performance: -88.95%
Average Trading Volume: 537,814
Current Market Cap: NOK241.2M
Find detailed analytics on BRRGF stock on TipRanks’ Stock Analysis page.